Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alcon

This article was originally published in The Tan Sheet

Executive Summary

Acquires ICaps dietary supplement from La Haye Labs, the companies announce. Alcon "believes that ICaps fills an important market niche," the company says. Formulated to "promote healthy eyes," ICaps TR (time-release) contains beta-carotene, vitamins C, E, and B2, zinc acetate, manganese and selenium, while ICaps Plus adds copper. "As people grow older, they can experience eye problems such as macular degeneration and cataracts. Today's better-informed consumers are searching for potential ways to maintain their eye health," Alcon notes. La Haye says a "growing percentage of ophthalmologists and optometrists now recommend antioxidants for their patients"

Acquires ICaps dietary supplement from La Haye Labs, the companies announce. Alcon "believes that ICaps fills an important market niche," the company says. Formulated to "promote healthy eyes," ICaps TR (time-release) contains beta-carotene, vitamins C, E, and B2, zinc acetate, manganese and selenium, while ICaps Plus adds copper. "As people grow older, they can experience eye problems such as macular degeneration and cataracts. Today's better-informed consumers are searching for potential ways to maintain their eye health," Alcon notes. La Haye says a "growing percentage of ophthalmologists and optometrists now recommend antioxidants for their patients".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel